179 filings
S-8
IMVT
Immunovant Inc
15 Apr 24
Registration of securities for employees
4:16pm
10-Q
2024 Q3
IMVT
Immunovant Inc
Quarterly report
12 Feb 24
7:05am
8-K
IMVT
Immunovant Inc
12 Feb 24
Results of Operations and Financial Condition
7:02am
8-K
IMVT
Immunovant Inc
9 Jan 24
Regulation FD Disclosure
8:08am
8-K
IMVT
Immunovant Inc
20 Dec 23
Immunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
4:37pm
8-K
tyfx6odjqfv8
28 Nov 23
Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential
7:43am
S-3ASR
mtmq6cgyi0r ei
9 Nov 23
Automatic shelf registration
8:49am
8-K
wbw07b0xd uycasqh9b
9 Nov 23
Results of Operations and Financial Condition
7:06am
424B5
epzdh
29 Sep 23
Prospectus supplement for primary offering
4:48pm
8-K
855bpulyxn2ul
28 Sep 23
Entry into a Material Definitive Agreement
5:23pm
FWP
zucpbu1wenl7r63xqd6v
28 Sep 23
Free writing prospectus
6:09am
FWP
bepk839
26 Sep 23
Free writing prospectus
8:00pm
424B5
7lpx5y1
26 Sep 23
Prospectus supplement for primary offering
5:28pm
8-K
lxs7w75ab in0
26 Sep 23
Immunovant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results
7:45am
8-K
suzt0n99
23 Aug 23
Submission of Matters to a Vote of Security Holders
4:48pm
8-K
9p7tbxk xvrx01jggnsi
10 Aug 23
Results of Operations and Financial Condition
7:10am
DEFA14A
pat 5cgehmyrsnrk8rj
26 Jun 23
Additional proxy soliciting materials
7:35am